

BIOLIDICS LIMITED
(Company Registration Number: 200913076M)

**SIGNING OF MANUFACTURER AGREEMENT FOR
RAPID TEST KITS TO DETECT NOVEL CORONAVIRUS 2019**

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") is pleased to announce that the Company had entered into a manufacturer agreement (the "**Agreement**") with a diagnostic kit manufacturer for a duration of one (1) year to customise and manufacture the Company's rapid test kits for the detection of the Novel Coronavirus 2019 (the "**COVID-19 Rapid Test Kits**"). The first batch of the COVID-19 Rapid Test Kits is expected to be available in April 2020.

The COVID-19 Rapid Test Kits have received provisional authorisation from Singapore's Health Sciences Authority (HSA) to be used in Singapore.

Save for their respective shareholdings in the Company (if any), none of the Directors or substantial shareholders of the Company has any interest, direct or indirect in the Agreement.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Non-Executive Non-Independent Chairman
30 March 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.